Ventana holds firm against third extension of Roche bid:
This article was originally published in Clinica
Ventana Medical Systems has remained steadfast in its opposition of Roche's hostile takeover despite the tender offer being extended until November 1. Ventana issued a statement saying: "This is now the third time that Roche has extended its offer, one which we have previously said is grossly inadequate and one that substantially all of our investors have rejected repeatedly". The previous extension was due to expire on September 20 (see Clinica No 1271, p 3), at which time only 0.2% of Ventana's 34 million outstanding shares had been tendered to the Swiss drugs giant.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.